Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
18 Feb 2021
Treatment with tanezumab appears to relieve pain and improve physical function in patients with hip or knee osteoarthritis (OA), but may lead to dose-dependent increase in joint safety events as compared with nonsteroidal anti-inflammatory drug (NSAID), according to the results of a phase III safety trial.
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Proton beam radiotherapy matches radiofrequency ablation in recurrent/residual HCC

2 days ago

Proton beam radiotherapy (PBT) is a tolerable and safe approach to recurrent/residual hepatocellular carcinoma (rHCC) that yields comparable local progression-free survival (LPFS) rates to radiofrequency ablation (RFA), reports a recent study.

A total of 144 rHCC patients (tumour size < 3cm, number ≤ 2) participated in the study and were randomly allocated to PBT (n=72; median age, 60 years; 84.7 percent male) or RFA (n=72; median age, 61.5 years; 81.9 percent male) groups. Treatment cross-over was allowed in patients where the treatment assignment was technically infeasible. The primary outcome of interest was 2-year LPFS, and a per-protocol noninferiority margin of 15 percent was set.

After considering crossovers, the per-protocol analysis included 80 and 56 patients who received PBT and RFA, followed for a median of 51.6 and 50.7 months, respectively.

The 2-year per-protocol LPFS rate in the PBT group was 94.8 percent, while RFA conferred a corresponding rate of 83.9 percent. The resulting difference value was 10.9 percent, which met the criteria for noninferiority.

Similarly, in an intention-to-treat analysis, the 2-year LPFS rates for PBT and RFA were 92.8 percent and 83.2 percent, respectively, which also achieved noninferiority. Hazard ratios were likewise not significantly different between the treatment arms.

In terms of safety and tolerability, both groups displayed comparable incidence rates of leukopaenia, thrombocytopaenia, and hyperbilirubinaemia, and hypoalbuminaemia. Grade 3 adverse events occurred significantly more frequently in patients who received RFA (16.1 percent vs 0 percent; p<0.001), but all episodes were transient; all patients recovered.

There were no cases of treatment-related late hepatic failure and death without evidence of disease progression in either group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
18 Feb 2021
Treatment with tanezumab appears to relieve pain and improve physical function in patients with hip or knee osteoarthritis (OA), but may lead to dose-dependent increase in joint safety events as compared with nonsteroidal anti-inflammatory drug (NSAID), according to the results of a phase III safety trial.
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.